145 related articles for article (PubMed ID: 7910978)
1. Are there neurochemical indicators of risk for schizophrenia?
Csernansky JG; Newcomer JW
Schizophr Bull; 1994; 20(1):75-88. PubMed ID: 7910978
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
[TBL] [Abstract][Full Text] [Related]
3. Genomic influences on schizophrenia-related neurotransmitter systems.
Keltner NL
J Nurs Scholarsh; 2005; 37(4):322-8. PubMed ID: 16396404
[TBL] [Abstract][Full Text] [Related]
4. Schizophrenia: comments on genes, development, risk factors, phenotype, and course.
Lieberman JA
Biol Psychiatry; 1999 Oct; 46(7):869-70. PubMed ID: 10509169
[No Abstract] [Full Text] [Related]
5. Biological studies in schizophrenia.
Meltzer HY
Schizophr Bull; 1987; 13(1):77-111. PubMed ID: 3602940
[TBL] [Abstract][Full Text] [Related]
6. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
Guise S; Soubrouillard C; Blin O
Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
[TBL] [Abstract][Full Text] [Related]
7. [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].
Glenthøj BY; Mackeprang T; Bille AE; Hemmingsen RP
Ugeskr Laeger; 1999 Mar; 161(10):1391-8. PubMed ID: 10085745
[TBL] [Abstract][Full Text] [Related]
8. The genetics of schizophrenia is the genetics of neurodevelopment.
Jones P; Murray RM
Br J Psychiatry; 1991 May; 158():615-23. PubMed ID: 1860016
[No Abstract] [Full Text] [Related]
9. Neuropsychological risk indicators for schizophrenia: a review of family studies.
Kremen WS; Seidman LJ; Pepple JR; Lyons MJ; Tsuang MT; Faraone SV
Schizophr Bull; 1994; 20(1):103-19. PubMed ID: 8197409
[TBL] [Abstract][Full Text] [Related]
10. Clinical phenomenology.
Andreasen NC; Shore D; Burke JD; Grove WM; Lieberman JA; Oltmanns TF; Pettegrew JW; Pulver AE; Siever LJ; Tsuang MT
Schizophr Bull; 1988; 14(3):345-63. PubMed ID: 2905523
[No Abstract] [Full Text] [Related]
11. The neuropsychology of schizophrenia: a neurodevelopmental and case study approach.
Seidman LJ
J Neuropsychiatry Clin Neurosci; 1990; 2(3):301-12. PubMed ID: 2136090
[No Abstract] [Full Text] [Related]
12. [Molecular genetics of cognitive deficit in schizophrenia].
Golimbet VE
Mol Biol (Mosk); 2008; 42(5):830-9. PubMed ID: 18988532
[TBL] [Abstract][Full Text] [Related]
13. The neurobiology of schizophrenia.
Littrell RA; Schneiderhan M
Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997
[TBL] [Abstract][Full Text] [Related]
14. A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies.
Portin P; Alanen YO
Acta Psychiatr Scand; 1997 Jan; 95(1):1-5. PubMed ID: 9051153
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
16. [Neurobiology of schizophrenia].
Henn FA
Schweiz Arch Neurol Psychiatr (1985); 1995; 146(5):224-9. PubMed ID: 8658103
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
Harrison PJ
Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
[No Abstract] [Full Text] [Related]
18. Dissociation of neurocognitive deficits in a monozygotic twin pair concordant for schizophrenia.
Condray R; Steinhauer SR; van Kammen DP; Zubin J
J Neuropsychiatry Clin Neurosci; 1992; 4(4):449-53. PubMed ID: 1422174
[TBL] [Abstract][Full Text] [Related]
19. [Psychopharmacologic approaches to schizophrenic psychoses].
Giacardy-Paty M; Soubrouillard C; Blin O
Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
